SCTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Scribe Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 2, 2026
$19.39−0.69 (-3.44%)
Close on Oct 19, 2026
- Market cap
- $48.01M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
3 of Scribe Therapeutics's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Jun 30, 2026 | Sep 2, 2026 | SEC EDGAR |
| Current report | 8-K | Sep 2, 2026 | Sep 2, 2026 | SEC EDGAR |
| Current report | 8-K | Jul 27, 2026 | Jul 27, 2026 | SEC EDGAR |